SFDA Grants Marketing Authorization for Two Saudi-Developed AI-Enabled Medical Software Products for Dental and Ophthalmic Diagnosis

The Saudi Food and Drug Authority (SFDA) has granted marketing authorization for two locally developed, AI-enabled medical software products designed to support dental and ophthalmic diagnosis, "Dental IQ" and "SAARIA." The authorization was granted following a comprehensive regulatory review, including the assessment of technical documentation and clinical evidence to verify the software’s safety, performance, and effectiveness for its intended uses.

Enhancing Diagnostic Accuracy for Dental and Periodontal Diseases

The "Dental IQ" software utilizes deep learning algorithms to analyze dental X-ray images and support the identification of potential pathological findings, including dental caries, periodontal disease, and structural changes affecting the teeth and supporting tissues. This supports healthcare practitioners in improving diagnostic accuracy and informing appropriate treatment planning.

Enabling Early Detection of Diabetic Retinopathy

The "SAARIA" software utilizes AI technologies to analyze retinal (fundus) images to support the screening of diabetic patients and the early detection of diabetic retinopathy in healthcare settings. This supports the identification of patients who may require further specialized ophthalmic evaluation, thereby facilitating timely referral and interventions and helping to reduce the risk of disease-related complications.

National Leadership in AI-Driven Healthcare Solutions

These two products represent a significant national milestone as the first Saudi-developed AI-enabled medical software solutions in dentistry and ophthalmology to receive SFDA marketing authorization. Designed as clinical support tools, they assist healthcare practitioners in making informed clinical decisions.

A Saudi Milestone Strengthening the Kingdom's Position in Digital Health

Both software products were developed by Saudi startups specializing in AI-driven digital health solutions. The companies enrolled in the SFDA’s Innovative Medical Devices Pathway, receiving early regulatory guidance and support and successfully fulfilling the applicable regulatory requirements. This included conducting local clinical studies in the Kingdom to validate the performance of their software in local healthcare settings and committing to post-marketing clinical follow-up plans to monitor real-world performance and ensure continued safe use.

Regulatory Disclaimer

The SFDA cautions against relying solely on the outputs of AI-enabled medical software for clinical decision-making. Such outputs are intended to support clinical decision-making and do not replace the healthcare professional’s clinical judgment. Healthcare professionals are responsible for reviewing and validating the outputs and making appropriate clinical decisions based on the patient’s condition.

A Regulatory Framework Supporting Future Innovation in Digital Health

The granting of marketing authorization for the software reflects the SFDA's strategic commitment to fostering responsible innovation in digital health, supporting the localization of advanced medical technologies, and facilitating timely market access to safe, effective, and high-quality medical devices. This milestone also contributes to the broader objectives of the Health Sector Transformation Program and Saudi Vision 2030.